Following some earnings data for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), we note that the current quarter EPS consensus estimate is 0.69. This EPS estimate is using data provided by 4 sell-side analysts polled by Zacks Research. This consensus estimate may vary from other data outlets providing consensus projections. Last quarter, the company reported a quarterly EPS of 0.68. Investors often pay extra close to the actual numbers when they are reported. If the actual comes in way under what the analysts were predicting, investors might want to take a deeper look to see what is going on with the stock. Investors may also be on the lookout for positive surprises on earnings beats. When a company reports actual earnings results, the surprise factor may cause the stock price to move sharply in either direction. Because it is difficult to gauge how a stock will react after the earnings report, investors may trade with increased caution during this period of time.
Investors may be wondering what’s in store for the next few months in terms of the equity market. Many investors may be hesitant to get into the mix with markets still trading at such high levels. Sometimes, the fear of missing out on the next big run will cause investors to make hasty decisions. Taking the time to do the full research can help offset the jitters associated with picking stocks. Finding stocks that still have room to head higher can be tricky, but there are still plenty of them out there. Although nobody can say for certain which way the market will trend into the New Year, investors should be on the lookout for opportunities that may present themselves over the next quarter. All eyes will be focused on company earnings when the next round of earnings reports begins.
In the fast paced world of stock market investing, individuals are always looking for information to help provide an edge. Many investors will study sell-side analyst opinions to help assist with navigating the market. Turning the attention to shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), we can see that the current average broker rating is now 3.03. This rating is provided by Zacks Research using a scale from 1 to 5. Following this scale, a 1 would indicate a Strong Buy and a 5 would represent a Strong Sell rating. Digging a little deeper, we can see that out of the polled analysts, 2 rated the stock a Strong Buy or Buy. This average broker rating may help investors decide if they feel the same way about the stock as the professionals.
Investors might be trying to gauge which way shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will swing over the next couple of quarters. In recent trading activity, the stock has been seen near the $18.47 level. Many investors pay increased attention to shares when they are nearing notable historical highs or lows. Over the past 52 weeks, the stock has touched a high price of 25.65, and seen a low price of 14.59. Looking at some additional historical stock price information, we note that shares have seen a move -13% over the previous 12 weeks. If we pull in closer to look at performance over the past month, we see that shares have seen a change of 4.65%. Over the last 5 trading sessions, the stock has moved 4.53%. Investors will most likely be keeping their eyes peeled to see how the stock performs heading into the next round of earnings reports.
Investing in the stock market can sometimes be a wild ride. Without the proper planning and research, investors may quickly find themselves on the outside looking in. Doing the research and studying the market can be helpful, but creating a trading or investing plan may be the most important part of the process. When the back testing and practice is completed, the real challenge awaits. The practice and preparation can be very helpful for understanding the market, but when real money gets put on the line, it can be a whole different ballgame. The more successful traders and investors are the ones who are able to stay focused and disciplined even throughout turbulent market situations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.